|1.||Hemmings, Brian A: 6 articles (01/2015 - 07/2003)|
|2.||Hergovich, Alexander: 5 articles (01/2015 - 07/2009)|
|3.||Lai, Zhi-Chun: 5 articles (11/2013 - 03/2005)|
|4.||Cornils, Hauke: 4 articles (01/2015 - 11/2009)|
|5.||Guan, Kun-Liang: 4 articles (07/2012 - 11/2007)|
|6.||Kohler, Reto S: 3 articles (06/2011 - 11/2009)|
|7.||Yang, Xiaolong: 3 articles (10/2010 - 02/2008)|
|8.||Zhao, Bin: 3 articles (06/2010 - 11/2007)|
|9.||Shimizu, Takeshi: 3 articles (02/2008 - 03/2005)|
|10.||Wei, Xiaomu: 3 articles (11/2007 - 03/2005)|
|1.||Neoplasm Metastasis (Metastasis)
11/01/2013 - "Both the ATA and LATS risk stratification systems provided clinically meaningful graded estimates with regard to (i) the likelihood of achieving remission in response to initial therapy, (ii) the likelihood of having persistent structural disease in response to initial therapy and at final follow-up, (iii) the likely locations of the persistent structural disease (locoregional vs. distant metastases), (iv) the likelihood of recurrence, and (v) the likelihood of being no evidence of disease at final follow-up. "
05/01/2014 - "Fifty-two LATs were malignant (64%): adrenocortical carcinoma (44%), metastasis (27%) and pheochromocytoma (21%). "
06/01/2015 - "In this study, we explored the expression levels of LATS family members in ovarian tumors using normal ovaries, fallopian tubes, and endometrium as controls. "
08/03/2015 - "Inhibition of FAK or Src in MCF-10A cells plated at low cell density prevented the activation of Yes-associated protein (YAP) in a large tumor suppressor homologue (Lats)-dependent manner. "
06/01/2014 - "The findings that both AMPK and Mst/Lats mediate the antitumor activity of C19 shed light on a potential cross-talk between metabolic and organ size control pathways in regulating cancer progression. "
05/01/2014 - "Large adrenal tumors (LATs, ≥6 cm) are uncommon and associated with malignancy in 25% of cases. "
03/13/2014 - "Although post-translational modification-especially MST/Lats (large tumor suppressor)-mediated phosphorylation and PP1 (protein phosphatase-1)-mediated dephosphorylation-has been found to regulate the activity of YAP2, very little is known about its acetylation. "
|3.||Graves Disease (Basedow Disease)
05/01/1984 - "Overall, the study indicates that serum LATS-P is related to the clinical course of Graves' disease but there remains a minority of patients in whom the activity cannot be detected."
04/01/1997 - "Members of the Latin American Thyroid Society (LATS) (235 physicians) were surveyed by a questionnaire on their management of Graves' disease, and the survey procedure was the same used by the other thyroid societies. "
06/01/1986 - "Changes in c-TRAb, p-TRAb and LATS activity in the clinical course of patients with Graves' disease were examined. "
06/01/1984 - "The positive TRAb was not changed in 4 Graves' disease patients whose LATS activity had disappeared following antithyroid treatment. "
03/19/1983 - "Activities of serum long acting thyroid stimulator protector were measured in a series of nine pregnancies in eight mothers who had Graves' disease, one of whom had been successfully treated by surgery. "
11/10/2014 - "The mammalian Misshapen homolog MAP4K4 similarly interacts with LATS (Warts homolog) and promotes inhibition of YAP (Yorkie homolog). "
03/11/2013 - "An EGFR-Hippo pathway link is conserved in mammals, as activation of EGFR or RAS activates the Yorkie homolog YAP, and EGFR-RAS-MAPK signaling promotes phosphorylation of the Ajuba family protein WTIP and also enhances WTIP binding to the Warts and Salvador homologs LATS and WW45. "
09/09/2005 - "The growth regulators warts/lats and melted interact in a bistable loop to specify opposite fates in Drosophila R8 photoreceptors."
09/15/2004 - "The Drosophila melanogaster warts/lats tumour suppressor has two mammalian counterparts LATS1/Warts-1 and LATS2/Kpm. "
11/01/2002 - "Recently, LATS2, a new human homologue of the Drosophila tumor suppressor gene (lats/warts) was identified on 13q11-12. "
04/01/2006 - "Our study assessed MRSA burden in Texas 4A and 5A high school athletic departments by contacting 447 licensed athletic trainers (LATs) regarding skin infections in athletes; 186 (41.6%) responded. "
09/15/1996 - "At survival times of > 30 d after inoculation, we found that (1) infectious virus was not detectable by titration and immunohistochemical studies; (2) neurons harbored virus as demonstrated by the detection of the LATs by in situ hybridization (ISH); (3) transcripts expressed during the lytic cycle of infection were not detected by ISH; and (4) subsets of neurons were selectively vulnerable to latent infection, depending on the site of inoculation. "
12/01/1991 - "Many recent studies of latent herpes simplex virus type 1 (HSV-1) infections within the nervous system have focused on the diploid genes encoding the latency-associated transcripts (LATs). "
12/01/2014 - "The amounts of viral genomes, and those of four types of viral transcripts (immediate-early, early and late, together with latency-associated transcripts [LATs]), were measured by quantitative PCR and RT-PCR in the main sites of HSV1 latent infection at 6 days, 1 and 3 months post inoculation, and the number of LAT-expressing neurons was assessed by in-situ hybridization on histological sections of trigeminal ganglia (TG). "
08/01/2012 - "We conclude that the HSV-1 LATs facilitate the long-term stability of the latent cell population within the infected host and that interpretation of LAT establishment phenotypes is influenced by infection methodology."
|1.||Long-Acting Thyroid Stimulator (LATS)
|5.||Protein Kinases (Protein Kinase)
|6.||Thyrotropin (Thyroid-Stimulating Hormone)
|8.||Immunoglobulin G (IgG)
|10.||Thyrotropin Receptors (Thyrotropin Receptor)